AAPL327.50+12.64 (+4.01%) ▲|ABBV244.11+1.06 (+0.44%) ▲|ABT89.27+0.94 (+1.06%) ▲|ACN137.02+2.46 (+1.83%) ▲|ADBE224.56+3.78 (+1.71%) ▲|AMAT579.43-16.27 (-2.73%) ▼|AMD529.14-18.99 (-3.46%) ▼|AMGN358.32+3.07 (+0.86%) ▲|AMT168.63-0.20 (-0.12%) ▼|AMZN254.96+7.47 (+3.02%) ▲|AVGO394.28+5.17 (+1.33%) ▲|AXP358.44+3.38 (+0.95%) ▲|BA218.12+1.01 (+0.47%) ▲|BAC61.59+0.97 (+1.60%) ▲|BKNG182.80+7.95 (+4.55%) ▲|BLK1,093.40+67.96 (+6.63%) ▲|BMY58.72+1.77 (+3.11%) ▲|BNY162.35+7.85 (+5.08%) ▲|BRK-B488.35-2.74 (-0.56%) ▼|C134.89+1.62 (+1.22%) ▲|CAT914.30-19.04 (-2.04%) ▼|CL91.47+0.44 (+0.48%) ▲|CMCSA23.49+0.30 (+1.29%) ▲|COF208.89+3.60 (+1.75%) ▲|COP111.46-0.41 (-0.37%) ▼|COST916.54-5.21 (-0.57%) ▼|CRM167.00-0.56 (-0.33%) ▼|CSCO111.77-5.32 (-4.54%) ▼|CVS105.91-0.27 (-0.25%) ▼|CVX181.60-0.16 (-0.09%) ▼|DE589.48+5.08 (+0.87%) ▲|DHR200.79+1.74 (+0.87%) ▲|DIS97.15+1.28 (+1.34%) ▲|DUK124.34-2.03 (-1.61%) ▼|EMR136.25+0.16 (+0.12%) ▲|FDX313.42-0.24 (-0.08%) ▼|GD365.63-3.87 (-1.05%) ▼|GE360.35+6.62 (+1.87%) ▲|GEV1,055.28-10.73 (-1.01%) ▼|GILD131.70+1.66 (+1.28%) ▲|GM77.64+0.77 (+1.00%) ▲|GOOG370.21+12.88 (+3.60%) ▲|GOOGL370.92+11.41 (+3.17%) ▲|GS1,152.07+12.07 (+1.06%) ▲|HD341.44+3.70 (+1.10%) ▲|HON222.84+0.16 (+0.07%) ▲|IBM211.20-5.87 (-2.70%) ▼|INTC102.99-4.77 (-4.43%) ▼|INTU279.70-2.73 (-0.97%) ▼|ISRG388.97+9.47 (+2.50%) ▲|JNJ247.02-6.83 (-2.69%) ▼|JPM346.91+4.02 (+1.17%) ▲|KO82.45-0.63 (-0.76%) ▼|LIN514.15-8.39 (-1.61%) ▼|LLY1,156.63+4.09 (+0.35%) ▲|LMT514.46-0.53 (-0.10%) ▼|LOW209.66+1.98 (+0.95%) ▲|LRCX335.43-10.67 (-3.08%) ▼|MA535.21-2.81 (-0.52%) ▼|MCD264.95-3.99 (-1.48%) ▼|MDLZ58.72-0.08 (-0.14%) ▼|MDT80.47+1.17 (+1.48%) ▲|META681.31+20.27 (+3.07%) ▲|MMM160.53+3.95 (+2.52%) ▲|MO70.52+0.36 (+0.51%) ▲|MRK123.61+2.83 (+2.34%) ▲|MS228.55+0.88 (+0.39%) ▲|MSFT395.63+10.70 (+2.78%) ▲|MU904.28-78.84 (-8.02%) ▼|NEE89.10-0.44 (-0.49%) ▼|NFLX73.68+0.15 (+0.20%) ▲|NKE42.77-0.09 (-0.21%) ▼|NOW104.73-0.12 (-0.11%) ▼|NVDA212.50+0.70 (+0.33%) ▲|ORCL132.49+4.55 (+3.56%) ▲|PEP135.40-0.05 (-0.04%) ▼|PFE24.82+0.57 (+2.35%) ▲|PG148.05+1.97 (+1.35%) ▲|PLTR133.76+0.04 (+0.03%) ▲|PM180.88+4.93 (+2.80%) ▲|QCOM177.98-0.12 (-0.07%) ▼|RTX195.89+2.50 (+1.29%) ▲|SBUX105.11-1.06 (-1.00%) ▼|SCHW102.79+1.69 (+1.67%) ▲|SO94.60-1.36 (-1.42%) ▼|SPG222.01+0.73 (+0.33%) ▲|T21.43+0.15 (+0.70%) ▲|TMO535.29+1.22 (+0.23%) ▲|TMUS187.62+0.49 (+0.26%) ▲|TSLA394.46-1.72 (-0.43%) ▼|TXN301.19-4.36 (-1.43%) ▼|UBER72.67+0.59 (+0.82%) ▲|UNH418.52-6.67 (-1.57%) ▼|UNP288.36+0.06 (+0.02%) ▲|UPS112.94-0.73 (-0.64%) ▼|USB63.01+0.87 (+1.40%) ▲|V355.14-0.88 (-0.25%) ▼|VZ42.83+0.36 (+0.85%) ▲|WFC87.51+2.22 (+2.60%) ▲|WMT112.53-1.17 (-1.03%) ▼|XOM144.51-0.58 (-0.40%) ▼|AAPL327.50+12.64 (+4.01%) ▲|ABBV244.11+1.06 (+0.44%) ▲|ABT89.27+0.94 (+1.06%) ▲|ACN137.02+2.46 (+1.83%) ▲|ADBE224.56+3.78 (+1.71%) ▲|AMAT579.43-16.27 (-2.73%) ▼|AMD529.14-18.99 (-3.46%) ▼|AMGN358.32+3.07 (+0.86%) ▲|AMT168.63-0.20 (-0.12%) ▼|AMZN254.96+7.47 (+3.02%) ▲|AVGO394.28+5.17 (+1.33%) ▲|AXP358.44+3.38 (+0.95%) ▲|BA218.12+1.01 (+0.47%) ▲|BAC61.59+0.97 (+1.60%) ▲|BKNG182.80+7.95 (+4.55%) ▲|BLK1,093.40+67.96 (+6.63%) ▲|BMY58.72+1.77 (+3.11%) ▲|BNY162.35+7.85 (+5.08%) ▲|BRK-B488.35-2.74 (-0.56%) ▼|C134.89+1.62 (+1.22%) ▲|CAT914.30-19.04 (-2.04%) ▼|CL91.47+0.44 (+0.48%) ▲|CMCSA23.49+0.30 (+1.29%) ▲|COF208.89+3.60 (+1.75%) ▲|COP111.46-0.41 (-0.37%) ▼|COST916.54-5.21 (-0.57%) ▼|CRM167.00-0.56 (-0.33%) ▼|CSCO111.77-5.32 (-4.54%) ▼|CVS105.91-0.27 (-0.25%) ▼|CVX181.60-0.16 (-0.09%) ▼|DE589.48+5.08 (+0.87%) ▲|DHR200.79+1.74 (+0.87%) ▲|DIS97.15+1.28 (+1.34%) ▲|DUK124.34-2.03 (-1.61%) ▼|EMR136.25+0.16 (+0.12%) ▲|FDX313.42-0.24 (-0.08%) ▼|GD365.63-3.87 (-1.05%) ▼|GE360.35+6.62 (+1.87%) ▲|GEV1,055.28-10.73 (-1.01%) ▼|GILD131.70+1.66 (+1.28%) ▲|GM77.64+0.77 (+1.00%) ▲|GOOG370.21+12.88 (+3.60%) ▲|GOOGL370.92+11.41 (+3.17%) ▲|GS1,152.07+12.07 (+1.06%) ▲|HD341.44+3.70 (+1.10%) ▲|HON222.84+0.16 (+0.07%) ▲|IBM211.20-5.87 (-2.70%) ▼|INTC102.99-4.77 (-4.43%) ▼|INTU279.70-2.73 (-0.97%) ▼|ISRG388.97+9.47 (+2.50%) ▲|JNJ247.02-6.83 (-2.69%) ▼|JPM346.91+4.02 (+1.17%) ▲|KO82.45-0.63 (-0.76%) ▼|LIN514.15-8.39 (-1.61%) ▼|LLY1,156.63+4.09 (+0.35%) ▲|LMT514.46-0.53 (-0.10%) ▼|LOW209.66+1.98 (+0.95%) ▲|LRCX335.43-10.67 (-3.08%) ▼|MA535.21-2.81 (-0.52%) ▼|MCD264.95-3.99 (-1.48%) ▼|MDLZ58.72-0.08 (-0.14%) ▼|MDT80.47+1.17 (+1.48%) ▲|META681.31+20.27 (+3.07%) ▲|MMM160.53+3.95 (+2.52%) ▲|MO70.52+0.36 (+0.51%) ▲|MRK123.61+2.83 (+2.34%) ▲|MS228.55+0.88 (+0.39%) ▲|MSFT395.63+10.70 (+2.78%) ▲|MU904.28-78.84 (-8.02%) ▼|NEE89.10-0.44 (-0.49%) ▼|NFLX73.68+0.15 (+0.20%) ▲|NKE42.77-0.09 (-0.21%) ▼|NOW104.73-0.12 (-0.11%) ▼|NVDA212.50+0.70 (+0.33%) ▲|ORCL132.49+4.55 (+3.56%) ▲|PEP135.40-0.05 (-0.04%) ▼|PFE24.82+0.57 (+2.35%) ▲|PG148.05+1.97 (+1.35%) ▲|PLTR133.76+0.04 (+0.03%) ▲|PM180.88+4.93 (+2.80%) ▲|QCOM177.98-0.12 (-0.07%) ▼|RTX195.89+2.50 (+1.29%) ▲|SBUX105.11-1.06 (-1.00%) ▼|SCHW102.79+1.69 (+1.67%) ▲|SO94.60-1.36 (-1.42%) ▼|SPG222.01+0.73 (+0.33%) ▲|T21.43+0.15 (+0.70%) ▲|TMO535.29+1.22 (+0.23%) ▲|TMUS187.62+0.49 (+0.26%) ▲|TSLA394.46-1.72 (-0.43%) ▼|TXN301.19-4.36 (-1.43%) ▼|UBER72.67+0.59 (+0.82%) ▲|UNH418.52-6.67 (-1.57%) ▼|UNP288.36+0.06 (+0.02%) ▲|UPS112.94-0.73 (-0.64%) ▼|USB63.01+0.87 (+1.40%) ▲|V355.14-0.88 (-0.25%) ▼|VZ42.83+0.36 (+0.85%) ▲|WFC87.51+2.22 (+2.60%) ▲|WMT112.53-1.17 (-1.03%) ▼|XOM144.51-0.58 (-0.40%) ▼|
25.9 C
New York
Thursday, July 16, 2026

Tag: development

newssourceFORcompanyinformationcontent1releasesmarket

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine’s DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed...

Indonesian DPR Immerses in Shenzhen’s Cutting-Edge Tech during SZMG’s “Telling China’s Story” Event, Calls for Deeper China-Indonesia Cooperation.

SHENZHEN, China, June 23, 2025 /PRNewswire/ -- This year marks the 75th anniversary of the establishment of diplomatic relations between China and Indonesia. Telling...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Fletcher Zone Maiden Mineral Resource of 2.3Moz

Stage 1 Fletcher Resource almost doubles the current Beta Hunt Resource PERTH, Western Australia, June 23, 2025 /CNW/ - Westgold Resources Limited (ASX: WGX) (TSX: WGX)...

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s CHICAGO, June 22, 2025 /PRNewswire/ -- A recent study found that oral semaglutide offers meaningful cardiovascular benefits...

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data...

Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Revolutionary Research by Dr. Takuma Hayashi Uncovers Molecular Origins of Deadly Uterine Cancer and Charts New Path for Treatment

In a landmark advancement for women's cancer research, Dr. Takuma Hayashi and his team have made groundbreaking discoveries that could transform our understanding and...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy

Once-weekly insulin helped patients achieve an average A1C of 6.92% in QWINT-1 trial Results support once-weekly insulin as effective alternative to daily treatment CHICAGO, June 22,...

Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes

Findings Highlight Potential for Novel Approach to Insulin Delivery in Pediatric Population CHICAGO, June 22, 2025 /PRNewswire/ -- Today, a new study demonstrates inhaled insulin...

Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength

GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences...

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DV

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers